FindTrial
Sign In

An Clinical Pilot Study of Yttrium [90Y] Microspheres Transarterial Radioembolization (TARE) for the Treatment of Hepatic Malignancies

An Clinical Pilot Study of Yttrium [90Y] Microspheres Transarterial Radioembolization (TARE) for the Treatment of Hepatic Malignancies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077524
Enrollment
Unknown
Registered
2023-11-10
Start date
2023-11-13
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Malignancies

Interventions

Yttrium [90Y] Microspheres Transarterial Radioembolization (TARE) group:NA

Sponsors

The southwest hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
43 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. meets diagnostic criteria for primary and secondary hepatocellular carcinoma; 2. recurrence after prior surgery or ablation for curative purposes, not suitable for resection, transplantation, or ablation, or active lesions after up to two TACE treatments with yttrium [90Y] microspheres; 3. the presence of at least 1 measurable lesion according to the Modified Revised Evaluation Criteria for the Evaluation of Cure in Solid Tumors (mRECIST).

Exclusion criteria

Exclusion criteria: The information is incomplete and the existing information is not sufficient for the analysis of the data in this study.

Design outcomes

Primary

MeasureTime frame
ORR;—

Countries

China

Contacts

Public ContactHui Zhang

The southwest hospital of Army Medical University

1056811360@qq.com+86 136 3791 2611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026